Alectinib continuation beyond progression in ALK-positive non-small cell lung cancer with alectinib-refractory.

ABSTRACT:

Background

Alectinib, a next-generation anaplastic lymphoma kinase tyrosine kinase inhibitor (ALK-TKI), has demonstrated noteworthy efficacy in the treatment of non-small cell lung cancer (NSCLC). Unfortunately, 53.3% of untreated patients receiving first-line treatment with alectinib developed resistance to alectinib. However, despite the widespread use of alectinib, studies on the efficacy and safety of continuing alectinib with other necessary therapies after progression of alectinib and possible population of benefit are still limited.

Methods

This retrospective cohort study included fifteen patients with ALK-positive NSCLC from nine institutions in China who experienced disease progression after first- or second-line treatment and continued to receive alectinib t

SUBMITTER: Li Y 

PROVIDER: S-EPMC10891411 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature